Sector News

Teva announces appointment of new Chief Legal Officer

November 11, 2016
Life sciences

Teva Pharmaceutical Industries Ltd. today announced the appointment of Mr. David Stark to the position of Chief Legal Officer. Stark is joining the Company’s executive leadership team and will replace Mr. Richard Egosi, who is taking a leave of absence.

“David has been an integral part of Teva’s stellar legal team since his arrival to Teva in 2002,” stated Erez Vigodman, Teva’s President and CEO. “Having most recently served as Deputy Chief Legal Officer, David led the Legal Group on a number of key achievements including the successful negotiation and close of Actavis Generics and Anda, and a series of key legal wins. He has shown the leadership capabilities needed to provide Teva with the best counsel it requires in order to deliver on its strategy, fulfill its vision and navigate any challenges we encounter along the way.”

Vigodman added, “Rich has been invaluable throughout his 21-year tenure with the company and is looked upon throughout the generic industry as an insightful and innovative thinker, due to his success in initially propelling the US generic business to its leadership position. Rich has been a key contributor to Teva’s growth, providing professional expertise, guidance and insight to both its executive management and Board, as well cultivating an exemplary legal department. We are pleased he will continue his career at Teva and look forward to his continued contribution and support.”

David Stark – Key Biographical Details
David Stark has amassed over 20 years of legal experience beginning with a series of New York law firms followed by a distinguished career at Teva. Since joining Teva in 2002, Mr. Stark served in a series of roles of increased responsibility in Teva North America and Teva Americas between 2002 and 2013, including Senior Director, Deputy General Counsel, and Vice President and General Counsel. In 2013 he was appointed Senior Vice President and General Counsel, Global Specialty Medicines, adding the position of Deputy Chief Legal Officer in 2016. Between 2014 and 2015 he also served as Acting Chief Legal Officer.

Prior to joining Teva, Mr. Stark served as an associate in the litigation departments of Haight, Gardner, Poor & Havens (1994-1997), Chadbourne & Parke (1997-1998), and Willkie Farr & Gallagher (1998-2002).

Source: Teva

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach